While DNA intercalation is primarily studied for its therapeutic effects, it can also contribute to mutagenesis if not properly controlled. By causing structural changes in DNA, intercalating agents can potentially induce mutations that lead to cancer if they occur in critical genes such as oncogenes or tumor suppressor genes. This dual role underscores the importance of carefully balancing the therapeutic and mutagenic potentials of intercalating agents in cancer treatment.
